These medications carry a boxed warning about thyroid C-cell tumors (contraindicated with personal/family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2) and warnings about potential risks including pancreatitis, gallbladder disease, acute kidney injury with dehydration, and worsening diabetic retinopathy with rapid glucose reduction (particularly with semaglutide)
Retatrutide is a once-weekly injectable medicine developed by Eli Lilly that is being researched for obesity and metabolic health
The risk of hypoglycemia with tirzepatide remains low, consistent with other GLP-1 receptor agonists, particularly in the absence of concomitant Insulin or sulfonylureas (Frias et al
What percentage of insurance plans cover medications for obesity-related conditions
Enhanced Weight Reduction: Encouraging the body to use stored fat as an energy source
Butand this is importantit depends on a few things like what your cycles were like before, how long you took the medication, and how much weight you lost
